- Home
- TGTX vs PECO Comparison
TGTX vs PECO Comparison
Compare TGTX & PECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- PECO
- Stock Information
- Founded
- TGTX 1993
- PECO 1991
- Country
- TGTX United States
- PECO United States
- Employees
- TGTX N/A
- PECO N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- PECO Real Estate Investment Trusts
- Sector
- TGTX Health Care
- PECO Real Estate
- Exchange
- TGTX Nasdaq
- PECO Nasdaq
- Market Cap
- TGTX 4.2B
- PECO 4.6B
- IPO Year
- TGTX 1995
- PECO 2021
- Fundamental
- Price
- TGTX $33.09
- PECO $35.69
- Analyst Decision
- TGTX Strong Buy
- PECO Buy
- Analyst Count
- TGTX 4
- PECO 6
- Target Price
- TGTX $42.50
- PECO $37.80
- AVG Volume (30 Days)
- TGTX 2.0M
- PECO 745.5K
- Earning Date
- TGTX 11-03-2025
- PECO 10-23-2025
- Dividend Yield
- TGTX N/A
- PECO 3.48%
- EPS Growth
- TGTX N/A
- PECO 13.92
- EPS
- TGTX 0.36
- PECO 0.55
- Revenue
- TGTX $454,069,000.00
- PECO $694,639,000.00
- Revenue This Year
- TGTX $82.58
- PECO $9.12
- Revenue Next Year
- TGTX $44.99
- PECO $5.87
- P/E Ratio
- TGTX $88.20
- PECO $64.06
- Revenue Growth
- TGTX 30.96
- PECO 10.31
- 52 Week Low
- TGTX $21.16
- PECO $32.40
- 52 Week High
- TGTX $46.48
- PECO $40.12
- Technical
- Relative Strength Index (RSI)
- TGTX 54.72
- PECO 53.95
- Support Level
- TGTX $31.34
- PECO $35.27
- Resistance Level
- TGTX $32.56
- PECO $36.00
- Average True Range (ATR)
- TGTX 1.03
- PECO 0.46
- MACD
- TGTX -1.33
- PECO -1.90
- Stochastic Oscillator
- TGTX 99.06
- PECO 97.62
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About PECO Phillips Edison & Company Inc.
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interests, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on market of expertise designed to optimize property value and consistently deliver a great shopping experience.